Skip to main navigation Skip to search Skip to main content

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)

  • Tri Nguyen
  • , Rebecca Parker
  • , Elisa Hawkins
  • , Beata Holkova
  • , Victor Yazbeck
  • , Akhil Kolluri
  • , Maciej Kmieciak
  • , Mohamed Rahmani
  • , Steven Grant
  • Virginia Commonwealth University Health System
  • Virginia Commonwealth University

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

This article has been corrected: Due to errors in image assembly, the IVIS image for the control mouse (panel 3) was inadvertently duplicated as the volasertib-treated mouse (panel 2) at time 0 (d1) in Figure 6A. After reviewing the original files, the correct image for the volasertib-treated time 0 (d1) mouse (panel 2) was located. The corrected Figure 6A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented).

Original languageBritish English
Pages (from-to)5383-5384
Number of pages2
JournalOncotarget
Volume10
Issue number51
StatePublished - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms (Oncotarget (2017) 8 (31478-31493) DOI: 10.18632/oncotarget.15649)'. Together they form a unique fingerprint.

Cite this